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Multiple Myeloma (MM) is a malignant proliferation of clonal bone marrow (BM) 
plasma cells (PCs) in association with monoclonal protein.
1
 Despite the dramatic 
improvements in MM treatment achieved in the last decade, it is still an incurable 
disease. A better knowledge of the biological mechanisms involved in disease 
occurrence and progression has led to the development of several new, innovative, 
drugs that significantly improved patients outcome and renewed the therapeutic 
approach to the disease in the last years. However, resistance develops with a 40% 
survival at five-years.
2-6
 Moreover, despite the improvement of patient risk-
stratification systems at diagnosis, treatment outcome is often unpredictable due to 
the high degree of genomic heterogeneity and genomic instability which characterize 
the disease. In this view, novel therapeutic strategies capable to overcome disease 
heterogeneity and improve patient outcome are strongly needed.
7-8
  
A fundamental feature of all cancers is the metabolic reprogramming to promote 
growth, survival, proliferation, and long-term maintenance. The common feature of 
this altered metabolism is increased glucose uptake and fermentation of glucose to 
lactate, the so called “Warburg Effect”.9-12 Moreover, the non essential amino acid 
Glutamine complements glucose to meet cancer cells metabolic demands. In 
particular, some human tumors exhibit a high requirement for Gln for anabolic and 
metabolic processes, a condition that has been defined “Gln-addiction” leading to the 







Beside its role of carbon and nitrogen source for macromolecules synthesis, the 
metabolism of this non-essential amino acid support tumor growth by inducing 
essential amino acids uptake and activation of mTORC1 signaling pathways, which acts 
as regulator for protein translation and autophagy.
14-17
 Moreover, Gln maintains 
mitochondrial membrane potential and prevents oxidative damage driving Glutathione 
(GSH) and NADPH synthesis.
18
  
In the recent years the importance of Gln metabolism as therapeutic target began to 
be explored and emerging data suggest that inhibition of glutamine metabolism with 
small molecules results in an energetic crisis leading to cellular death.
19-21
 Emerging 
data suggest efficacy of Gln-deprivation also in MM cells which are unable to 
synthesize adequate amounts of Gln and, therefore, result highly sensitive to Gln-
transporters blockade or glutaminase inhibition.
22-24 
Several approaches are reported to achieve Glu-depletion including: uptake inhibition 
(Gln-transporters inhibitors), metabolism targeting (Glutaminase inhibitors) or serum 
depletion exploiting the glutaminase-activity of L-asparaginase drug (L-ASP). L-ASP is a 
bacterial-derived enzyme that induces serum aminoacidic deprivation by catalyzing the 
hydrolysis of asparagine in aspartic acid and ammonium and glutamine in glutamic acid 
and ammonium.
24-29
 Among the above mentioned strategies to obtain Gln-deprivation, 
L-ASP is already available in clinic as it represents a cornerstone for acute 
lymphoblastic leukemia (ALL) and some aggressive lymphomas treatment.  
Based on these observations, we aim to explore the therapeutic relevance of 





anti-MM drugs. Moreover we will analyze biological mechanisms supporting the 
effectiveness of the identified therapeutic strategies. 
 
2. MATHERIALS AND METHODS 
 
2.1 Cell lines, primary cells and reagents 
 
The HMCLs MM.1S, LP1, RPMI-8226, H929, MOLP8, U266 were provided by 
collaborators or purchased from ATCC (Manassas, Virginia) or DSMZ (Braunschweig, 
Germany). 
HMCLs were maintained in RPMI 8226 medium containing 10% fetal bovine serum 
(FBS), 2 g/L glucose, 2 mM L-glutamine (GIBCO, Life Technologies, Carlsbad, CA). 
Medium was additioned with 50 U/mL penicillin/streptomycin and L-glutamine to 
obtain a final L-glutamine concentration of 4 mM (GIBCO, Life Technologies, Carlsbad, 
CA). 
HEK-293T cell line was purchased from ATCC and cultured in DMEM containing 10% 
FBS (GIBCO, Life Technologies, Carlsbad, CA), 4mM glutamine, 50 U/ml penicillin, and 
50 U/ml streptomycin (GIBCO, Life Technologies, Carlsbad, CA). 
To perform experiments in conditions of amino acid deprivation cells were cultured in 
10% FBS MEM medium (Sigma-Aldrich) supplemented with penicillin/streptomycin. 
Primary CD138+ MM cells were obtained from BM aspirate of newly diagnosed MM 
patients with high disease burden. Mononuclear cells were isolated by Ficoll-Hypaque 





(Miltenyi Biotec, Bergisch-Gladbach, Germany) to obtain highly purified CD138+ cells. 
Cells were used immediately for viability assays in RPMI 8226 medium containing 4 
mM L-glutamine and 5ng/mL IL-6 to preserve primary CD138+ cells viability.  
Human bone marrow stromal cells (BMSC) were isolated from bone marrow aspirates 
of MM patients. Mononuclear cells were collected by gradient centrifugation and 
plated in growth medium containing DMEM high glucose 20% FBS and 4Mm L-
glutamine. The non-adherent cells were removed after 5 days and the adherent cells 
cultured for further use. 
Erwinia Chrysantemi-derived L-ASP was gently provided by Jazz Pharmaceuticals. 
Escherichia Coli-derived L-ASP was purchased by Sigma Aldrich (#3809). Carfilzomib 
was purchased from Selleckchem (#S2853). 
 
2.2 Cell viability and apoptosis assays 
 
For citotoxicity assays, cells viability was assessed by colorimetric method, directly 
adding an all in one solution of tetrazolium compound inner salt (MTS) and an electron 
coupling reagent to culture plates (Cell Titer 96® Aqueous, Promega Corporation, 
Madison, WI, USA). After an incubation time from 30’to 4 hours, absorbance was 
recorded at 490nm with a 96-well plate reader. 
Apoptosis was evaluated by flow cytometric analysis following Annexin V–FITC (BD 
Bioscences, 556419) and Propidium (PI) (BD Bioscences, 51-6621E) staining, according 





defined as the sum of early apoptotic (annexin V+PI−) and late apoptotic (annexin 
V+PI+) cells. 
Combination drugs screening with L-ASP plus PIs bortezomib and carfilzomib was 
investigated with an isobologram analysis (CalcuSyn software program, version 2, 
Biosoft). 
 
2.3 Cell cycle and mitochondrial potential membrane analysis  
 
Cell-cycle profiles were obtained by staining cells with propidium iodide (PI; 50 μg/ml) 
in hypotonic lysis solution (0.1% (w/v) sodium citrate, 0.1% (v/v) Triton X-100) and 
incubating at 4°C for 24hours before analysis by flow cytometry. 
Mitochondrial potential membrane was measured by flow cytometric analysis after a  
15’ incubation with 50 nM tetramethylrhodamine ethyl ester (TMRE). 
 
2.4 Intracellular NAD+ measurement 
 
To evaluate the content of intracellular NAD, cells were plated at a density of 10
6
 
cells/well in 12-well plates and treated with different drugs. After 24 hrs of drug 
exposure, controls and treated cells were lysed in 0.05 ml of 0.6 M PCA at 4°C. Cell 
extracts were centrifuged for 3 min at 16, 000 x g, the supernatants were collected and 
an aliquot was diluted 20-fold in 100 mM sodium phosphate buffer, pH 8.0, for 
determination of NAD+ content, as described. NAD+ values were normalized to protein 








2.5 Lentiviral transduction 
 
pLV control and pLV c-MYC over-espressing lentiviral vectors were purchased from 
Vector Builder (Vector Builder Inc., Santa Clara, USA). For lentiviral transduction, 1× 10
6
 
293T cells were plated on 60 mm Petri dishes and allowed to adhere for 24 h. 
Thereafter, cells were transfected with 1μg of lentiviral plasmidic DNA and 700ng of 
each of three packaging vectors (pRP CMV VSVG; pRP CMV gag:pol RRE; pRP CMV RSV 
Rev), using TransIT-293 (Mirus Bio, Madison, WI) according to the manufacturer's 
instructions. 48 and 72h after transfection, the supernatant containing lentiviral 
particles was harvested, filtered with a 0.45-μm-diameter filter, and used to infect MM 
cells. MM cells were spinoculated at 750g for 45 min in presence of 8 μg ml−1 
polybrene, (Santa Cruz Biotechnologies, CA), incubated with viral supernatant for 8 h 
and left overnight in normal culturing medium. The day after, a second cycle of 
infection was performed. Successfully infected cells were selected using a suitable 
concentration of puromycin (0,5-2 μg ml−1). 48 and 72 h after selection, the 
transduction efficiency was approximated by counting the proportion of cells 
expressing the fluorescent protein (GFP) using a fluorescence microscope (Nikon 
Eclipse 80i, Nikon, Melville, NY); and the c-MYC over expression was validated by 






2.6 Western blot 
 
Whole-cell lysates were prepared as previously described. 31 Protein concentrations 
were determined by Bradford assay (Bio-Rad, CA), and equivalent amounts (40-50μg) 
were subjected to SDS-PAGE, transferred to PVDF membranes immunoblotted with 
following antibodies: anti-GAPDH (#5174, CellSignaling Technology) -γ tubulin (#MA1-
850, ThermoFischer Scientific), -PARP1 (#9532, CellSignaling Technology), -Caspase3 
(#9662, Cell Signaling Technology), -c-Myc (#9402, Cell Signaling Technology), CDK4 
(#12790 Cell Signaling Technology) – CDK6 (#3136 Cell Signaling Technology) – p21 
(#2947 Cell Signaling Technology) – p27 (#3686 Cell Signaling Technology) -  Non-
phospho-4E-BP1 (Thr46) (#4923, Cell SignalingTechnology), peIF2alpha (#3398 Cell 
Signaling Technology) eIF2alpha (#5324, Cell Signaling Technology), Phospho-p70 S6 
Kinase (Thr389) (#9206,Cell Signaling Technology), phospho-Histone H2A.X (Ser139) 
(#05-636, Millipore), -RAD51 (#sc-8349, Santa Cruz Biotechnology) – ATF4 (#11815 Cell 
Signaling Technology) - CHOP (#2895 Cell Signaling Technology)  – pAMPK ( PA5-17831 
Thermo Scientific)– IRF4 (#4964 Cell Signaling Technology). 
Band intensities were quantified by Quantity One SW software (Bio-Rad Laboratories, 
Inc) using standard ECL Western Blotting Detection Reagents (Thermo Fisher Scientific, 
IL). Densitometric analysis of western blots was carried out using Image J software 








2.7 Oxidative stress  
 
To confirm the involvement of ROS in drug-induced apoptosis, HMCLs were treated 
with L-ASP, PI or combination in presence or absence of 10 mM N-acetylcysteine 





DNA damage was detected by confocal microscopy as previously described.
31
 The anti-
γH2AX antibody was from Millipore (Ser139, clone JBW301) and the secondary Alexa 
Fluor 488–conjugated antibody was from Jackson Immuno Research. Q-Nuclear was 
used to counterstain nuclei. The slides were then mounted with ProLong Gold Antifade 
reagent (Life Technologies Carlsbad, CA), and images were taken using a Leica TCS SP 
confocal laser scanning microscope (Leica Microsystems, Wetzlar, Germany), equipped 




RPMI 8226 cells were transfected by using the 4D-Nucleofector™ System (Lonza), 
according to manufacturer’s instruction. pCMV3-empty vector and pCMV3-PARP1-
overespressing plasmids was purchased from Sino Biological (Wayne, PA, USA).  For 
each nucleofection, 2 x 10
6 
 cells were pulsed with the DN-100 program, using Amaxa 





at the final concentrations of 500 nM. After 24h from nucleofection, cells were 








3.1 L-asparaginase treatment significantly impacts MM cell viability by inducing 
metabolic “shutdown”  
Recent data indicate that tumor cells, including MM, exhibit a “metabolic addctition” 
that could be therapeutically exploited. 32-34 We exploit the amino acidic-deprivation 
induced by L-ASP to target MM cells Gln-addiction. Since L-ASP from E. Chrysantemi 
exerts a 10-folder higher glutaminase activity in comparison with Escherichia Coli- 
derived formulation, we first tested the anti-MM activity of Erwinia Chrysanthemi-
derived L-ASP on a large cohort of HMCLs harboring different genetic background. As 
shown in Figure 1A, a significant dose- and time-dependent decrease of MM cells 
viability was observed,  with 50% inhibitory concentration (IC50) values that ranged 
from 0,03 U/mL to 0.25 U/mL at 48h. To support specificity of this compound, a 
reference compound with the same reported mechanism of action was also tested; 
remarkably, the anti-MM activity of E. Coli- derived L-ASP on MM1S and LP1 cells was 
weaker as compared to Erwinia Chrysanthemi-derived L-ASP (Figure 1B). Next, we 
tested the anti-tumor activity of L-ASP on primary MM cells from both newly-
diagnosed as well as relapsed patients. Importantly, such treatment yielded similar 
results in a time- and dose-dependent manner (data not shown), irrespectively from 







Figure 1. Erwinia Chrysanthemi derived L-ASP shows potent anti-MM activity. (A) A panel of HMCLs 
were treated with increasing doses of Erwinia Chrysanthemi -derived L-ASP (from 0.01 U/mL to 3 U/mL) 
in a 96 wells plate and then viability was assessed by a MTS-based assay at 48 h. On the right IC50 values 
of MM tested cell lines is shown, together with detailed description of genetic background. (B) MM.1S 
and LP1 cell lines were tested with E. Chrysantemi L-ASP in parallel with E. Coli L-ASP. Viability was 
assessed following 48h of treatment by MTS-based assay. Data represent the mean values ± SD and 
represent a minimum of triplicates. 
 
Importantly, although diminished metabolic activity after drug treatment at 24 hours, 
MM cells did not enhance their apoptotic rate as determined by Annexin V/Propidium 
Iodide flow cytometric analysis (data not shown). These data prompted us to 
hypothesize that MTS assay, by detecting metabolic cells status, overestimated L-ASP 
anti-MM activity. Indeed, drug-exposure increased PI positive cells (death cells) only in 
RPMI 8226, whilst mortality rate of almost all tested cells was not measurable. The 





Importantly, while single L-Asn withdrawal did not affect MM cells viability at all, the 
double amino-acidic deprivation as well as Gln-deletion fully summarized the anti-MM 
activity triggered by L-ASP treatment (Figure 2A). We aimed to demonstrate that L-ASP 
induces a “metabolic shutdown” by analyzing cell cycle phases of MM-treated cells. As 
shown in Figure 2B, a G0/G1 phase arrest was observed early after 24h of treatment. 
Mechanistically these events were triggered by cMYC downregulation which in turn, by 
inducing cyclin (CDK4 and CDK6) downregulation and p21 activation, impaired cell 
cycle progression. As a result, U266 cell line, which does not express c-MYC, were only 
minimally sensitive to L-ASP with no differences on cell cycle phases between treated 
and untreated cells. Overall these data supported crucial role played by this oncogene 
on L-ASP observed anti-MM activity. To confirm these data, a proteomic analysis was 
also performed. As shown in Figure 2D, L-ASP treatment resulted in a massive protein 
synthesis blockade as suggested by increased non-phospho 4EBP1 and decreased 
pP70S6K at 48 h which is mediated by ATF4 and CHOP upregulation.  




















Figure 2. c-MYC plays a crucial role in anti-MM activity of ErwiniaChrysanthemi derived L-ASP. (A) Cell 
death, measured by FACS analysis of PI stained cells, in different amino-acidic deprivation conditions or 
after 48 h of E.Chrysantemi-derived L-ASP treatment [0.5 U/mL]. (B) L-ASP treatment induces a G0/G1 
phase arrest after 24 h treatment as well as c-MYC and cyclins downregulation, as depicted in western 
blot. (C) U266 cell lines are resistant to L-ASP-induced cell cycle arrest. (D) L-ASP treatment [0.5 U/mL] 
induces a protein synthesis blockade as shown in western blot analysis of drug-treated MM1S cells at 







3.2 Targeting metabolism and proteasome activity triggers synergistic anti-MM 
activity and results independent from c-MYC downregulation 
 
As reported, targeting metabolic vulnerabilities could exert synergistic anti-tumor 
activity with established therapies.34-36 We therefore investigated the combinatory 
effects between L-ASP and drugs currently used for MM treatment, such as the 
proteasome inhibitors (PIs). In particular, we explored the impact of L-ASP treatment 
on MM cells sensitivity to both carfilzomib (KAR) and bortezomib (BZ). On the basis of 
our preliminary data, we selected concentrations of L-ASP and carfilzomib with only 
modest single agent MM cell citotoxicity in order to assess their combined citotoxicity. 
Enhanced citotoxicity of the combination treatment in comparison with either agent 
alone was observed in all MM cell lines (Figure 3A); isobologram and combination 
index analysis revealed strong synergism of the combination as compare to single 
agents, with a combination index (CI) <1.0 at all tested doses (data not shown). 
Similarly, potent synergistic activity was observed also on primary tumor cells collected 
from patients (both NDMM and RRMM), with a CI <1.0 with all tested doses. On the 
contrary, in healthy PBMCs, these drugs were not only poorly active, but they also 
failed to show any cooperation. Thus carfilzomib’s activity is not potentiated by L-ASP 
in PBMCs, likely due to their lower proteasome activity,37 suggesting therefore a 
favorable therapeutic index for such combination. We next examined the molecular 
mechanism whereby co-treatment triggers synergistic anti-MM cytotoxicity. These 
studies were performed at 24 hours to reduce the confounding effects of cell death 





typically observed during apoptosis, including an increase in the percentage of 
Annexin-V+/PI- (early apoptotic) and Annexin-V+/P+ (late apoptotic) cells (Figure 3A); 
increased proteolytic cleavage of caspase-3 and PARP-1 in WB analysis (Figure 3B). To 
formally assess the role of caspase activity in MM cell death in response to the stimuli 
under investigation, we made use of the pan-caspase inhibitor zVAD-fmk.  Since the 
latter strongly reduced cell death in response to L-ASP and KAR combination, we 
concluded that these compounds kill MM cells via caspase-mediated apoptosis. 
To gain insights into specific role played by each amino-acid depletion in the observed 
synergism, we kept PIs-treated MM cells in different culture medium conditions. Asn 
depletion alone did not enhance the anti-MM activity of PIs; by contrast, a significant 
increase of tumor cells toxicity was observed when Gln-starved cells were treated with 
increased doses of PIs.  
Based on the prominent role of the Bone Marrow microenvironment in the 
progression of MM, and in development of drug-resistance,
39,40
 we characterized the 
effect of the BM milieu on MM sensitivity to this combination. We treated tumor cells 
in IL-6 (10 ng/mL) or IGF-1 (100 ng/mL). As expected, IL-6 or IGF-1 all protected tumor 
cells from spontaneous apoptosis but, importantly, co-treatment preserved its efficacy 
in this context. Thus, compared to spontaneous apoptosis of MM cells, co-treatment 
increased cell death in MM cells cultured alone but preserved its activity in the 










Figure 3. L-ASP induces synergistic growth inhibitory effects in combination with carfilzomib 
regardless of protective role of BM microenvironment. (A) LP1 cells were treated with L-ASP [0.5 
U/mL], Carfilzomib [2 nM] or their combination. The percentage of apoptotic cells was measured after 48 
h treatment by FACS analysis following AV/PI staining. (B) Whole cell lysates from LP1cells treated 
with each drug and their combination were subjected to WB analysis and probed with indicated 
antibodies. GAPDH was used as loading control. (C) MM-1S cells were treated with L-ASP [0.5 U/mL], 
Carfilzomib [2.5-3.5 nM] and combination in the presence or absence of rhIL-6 [10 ng/mL] or rhIGF-1 
[100 ng/mL] for 48 hours. Viability was assessed by a MTS based assay. The results presented are a mean  
SD of triplicate samples 
 
Based on pivotal role played by c-MYC in the anti-MM activity of L-ASP, we next 
investigated its modulation in such synergism.  As shown in Figure 4B co-treatment 





However, c-MYC negative U266 cells did not show weaker sensitivity, thus suggesting 





Figure 4. Cellular events triggered by drugs co-treatment. (A) U266 (Myc negative cells) were treated 
with increasing doses of L-ASP and PI combination. Viability was assessed by MTS-based assay. (B) 
Whole cell lysates from MM1S cells treated with several each drug and their combination, were 
subjected to WB analysis and probed with indicated antibodies. GAPDH was used as loading control. 
 
To further support these results, we generated a stable c-MYC over-expressing U266 
line by employing a lentiviral transduction approach (U266-cMYC OE). As shown in 
Figure 5A, engineered MM cells exhibited higher L-ASP sensitivity but slight-carfilzomib 
resistance; as result L-ASP plus carfilzomib showed comparable efficacy on both 
control and cMYC-OE U266cells. Remarkably, similar results were achieved by using 







Figure 5. MYC is not crucial for anti-MM activity of observed synergism. (A) L-ASP and 
Carfilzomib alone were tested on U266 engineered cells. Control (dot line) and c-MYC-OE cells (dash 
line)  were treated with increasing doses of drugs and viability was measured after 48h by using an MTS 
based-assay. (B) The anti-MM activity effectiveness of drugs combination was measured on both U266 






3.3 Role of metabolic shortage in modulating response to carfilzomib in MM cells 
 
Next we investigated whether L-ASP and PI combination could affect MM cells viability 
due to impairment of metabolic processes. To gain insights into this phenomenon, we 
focused on intracellular levels of NAD+, a metabolite involved in maintenance of the 
mitochondrial membrane potential and cellular signaling.
41-43
 As shown in Figure 6A, 
combination effectively reduced intracellular NAD+ concentration in MM cells, 
whereas the single agents treatment failed to diminish intracellular NAD+ content. 
Therefore, these results are consistent with a deep metabolic shortage triggered by co-
treatment on MM cells. To investigate if intracellular NAD+ depletion could explain the 
synergism of L-ASP and PI combination,  single drugs and their combination were 
tested in standard culture conditions and in presence of 1mM NAD or 10 mM 
nichotinamide (NAM) and 10 uM nicotinic acid. The percentage of apoptotic cells was 
evaluated by cytofluorimetric analysis after AV/PI staining. Interestingly, the addition 
of NAD or its precursors to culture medium was not able to revert the efficacy of the 
combination (data not shown). 
The mitochondrial membrane potential (ΔΨm) is an essential component in the 
process of energy storage during oxidative Phosphorylation and it is tightly interlinked 
to many mitochondrial processes, including ATP synthesis and ROS. By using 
tetramethylrhodamine ethyl ester (TMRE) cell staining, we found that single agents 
treatment did not induce mitochondrial transmembrane potential (ΨΔm) dissipation in 







Figure 6. L-ASP plus carfilzomib induces potent anti-MM activity by triggering genotoxic stress. A) 
Intracellular NAD 
+
 concentration was measured in MM.1S, U266 and LP1 cell lines after 24 h of L-ASP, 
carfilzomib or their combination. Cells were plated at a density of 10^6 cells/well in 12-well plates. 
NAD+ values were normalized to protein concentrations, determined by Bradford assay. B) U266 cells 
were treated with single drugs and their combination for 48 h. Thereafter MM cells PBLs with conserved 
ΨΔm-high were quantified by flow-cytometry. 
 
 
3.4 Combined L-ASP and carfilzomib increases genomic instability and oxidative 
stress of MM cells  
 
Emerging data support existence of links between cancer metabolism and DNA 
damage, yielding opportunities to investigate these vulnerabilities in a wide range of 
tumors.
44,45
 To determine the impact of L-ASP plus carfilzomib combination on 





accumulation of DNA damage by monitoring DNA damage signaling activity following 
single agents or their combinations. Co-treatment markedly increased the 
accumulation of the lower-molecular-weight protein γH2AX than specific controls. 
Similarly, L-ASP and carfilzomib co-treatment improvedγH2AX cellular foci compared 
with single agents treatment (Figure 7A, B and C). Collectively these data suggest that 
amino-acids starvation makes MM cells more vulnerable to carfilzomib activity 
probably through impairment of DNA repairs mechanisms efficiency, which in turn 
results in higher degree of DNA damage. 
It has been previously reported that enhanced oxidative stress results in increased 
DNA damage observed in tumor cells.
45.47
 As result,  novel compounds have recently 
been described that exploit induction of ROS for treatment of cancer.
48
 As a result we 
assumed that increased ROS levels promote DNA damage and induce apoptosis in MM 
co-treated cells. To formally demonstrate this hypothesis, we pre-treated MM cells 
with an antioxidant reagent N-Acetyl-Lcysteine (NAC), which scavenges ROS by 
replenishing glutathione stores. As shown in Figure 7D, this approach resulted in a 
complete rescue in term of both viability and apoptotic features of MM exposed cells, 
and more importantly, such treatment resulted in improved DNA stability, as 
suggested by reduced γ-H2A.X levels compared with control. (Figure 7E). Altogether, 
these data demonstrate that co-treatment elicits DNA damage in MM cells by both 















Figure 7.  Whole cells lysate of MM treated cells were (A) subjected to western blot analysis or (B) fixed 
for immunofluorescence with γH2AX antibody and QNuclear. Scale bar 100 μm. (C) Data represent 
mean ± SD of 4 independent cell cultures, *** P < 0.001, shown is the percentage of cells showing >10 
foci. (D) Single agents and their combination were tested in U266 cell line with or without 10mM of 
NAC for 48 hours. Apoptotic cells rate was assessed by FACS analysis after AV/PI staining. (E) Whole 
cells lysate of MM treated cells were subjected to western blot analysis in absence or in presence of 








Despite the dramatic improvements in MM treatment achieved in the last decade, it is 
still an incurable disease. MM is scarcely responsive to conventional chemotherapies 
and median overall survival was approximately 3 years until the late 1990s.
1
 A better 
knowledge of the biological mechanisms involved in disease occurrence and 
progression has led to the development of several new, innovative, drugs that 
significantly improved patients outcome and renewed the therapeutic approach to the 
disease in the last years. At least 3 classes of agents targeting different biological 
mechanisms have become available: proteasome inhibitors, immunomodulatory 
agents, and monoclonal antibodies and have been incorporated into front-line 
treatment or in the relapsed/refractory setting.
4-6
 Moreover, despite the improvement 
of patient risk-stratification systems at diagnosis, treatment outcome is often 
unpredictable due to the high degree of genomic heterogeneity and genomic 
instability which characterize the disease.
3
 In this view, novel therapeutic strategies 
capable to overcome disease heterogeneity and improve patient outcome are strongly 
needed.  
As well as most tumors, MM cells reprogram their metabolism to sustain uncontrolled 
proliferation and survival and several tumor-associated signaling pathways play a key-
role in regulating metabolic processes in neoplastic cells.
9-13
 The oncogenic role of c-
MYC is well established in MM where it contributes to the malignant phenotype and 
disease progression.
49
 Interestingly it has been reported that in neuroblastoma cells 









Moving from recent observations that MM cells are highly reliant on Gln for metabolic 
processes
22-24 
we investigated the therapeutic relevance of Asparaginase-induced Gln 
depletion for MM treatment.
25-29
 Pioneering studies on pediatric acute lymphoblastic 
leukemia patients explored the inter-relationship between asparaginase activity, Asn 
and Gln deamination. Gln deamination is significantly associated with clinically 
attainable plasmatic L-ASP activity and it is required for optimal serum Asn 
deamination, enhancing L-ASP efficacy in ALL patients. In fact, ≥ 90% of Gln 
deamination must occur before optimal Asn deamination takes place, due to de novo 
Asn synthesis in the liver.
51
 
We observed that L-ASP treatment induces an early “metabolic shutdown” in HMCLs 
and MM primary cells as confirmed by cell cycle arrest in G1 phase and protein 
synthesis blockade in western blot analysis.  Amino-acidic deprivation however does 
not result in direct citotoxicity in most of tested cell lines and several days are needed 
to induce cell death via apoptosis. We observed that following L-ASP treatment, c-MYC 
downregulation impaired cell cycle progression by CDK4 and CDK6 downregulation and 
loss of inhibition of p21 transcription. Notably, U266 cell line showed the highest IC50 
value and did not show any modification of cell cycle progression under L-ASP 
treatment. A massive c-MYC downregulation was also observed in MM cells receiving 
L-ASP and PIs combination, suggesting a strong contribution of c-MYC downregulation 
driving the effectiveness of the combination, as already reported with Glutaminase-
inhibitor compound 968 and carfilzomib association.
36





effectiveness of L-ASP and PIs combination also in c-MYC negative U266 cell line, 
suggesting that the downregulation of the oncogene was not the main driver of the 
observed synergism.  
Moving forward we explored whether the effectiveness of the combination could be 
explained by the impairment of metabolic cellular processes and oxidative stress 
induction. Normal plasma cells synthesize and secrete antibodies, being highly reliant 
on proteasome function for the clearance of abnormal and mutated proteins and on 
the “unfolded protein response” (UPR) signaling pathways. Malignant plasma cells 
transformation results in higher protein synthesis rates which makes cells more 
dependent on UPR signaling and proteasome functions for the clearance of abnormal 
proteins and proteins in excess. The pharmacological inhibition of proteasome 
function results in the accumulation of unfolded proteins triggering endoplasmic 
reticulum (ER) stress, which has until recently been considered the major mediator of 
PIs citotoxicity.
52,53
 Unresolved ER stress is also responsible of reactive oxygen species 
(ROS) overproduction leading to oxidative stress in MM cells. Furthermore, recent 
reports disclosed the ability of PIs to directly induce oxidative stress in MM and other 
human cancer cells, underlying the importance of such mechanism in PIs citotoxicity.
55-
57
 We found that amino-acidic deprivation induced by L-ASP and PI co-treatment was 
able to induce loss of ΔΨm  in comparison to single treatment alone, suggesting 
oxidative stress-induction as the main driver of L-ASP and PIs synergism. As a result we 
hypothesized that increased ROS levels promote DNA damage and induce apoptosis in 
MM co-treated cells. To formally demonstrate this hypothesis, we pre-treated MM 





glutathione stores. This approach resulted in a complete rescue in term of both 
viability and apoptotic features of MM exposed cells, and more importantly, such 
treatment resulted in improved DNA stability, Altogether, these data demonstrate that 
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